University of Kentucky Launches Clinical Outcomes-Based Educational Initiative to Reinforce Rheumatoid Arthritis Standards of Care

Business Wire, Oct 28, 2008

Program to Address Physician Gaps in Managing Rheumatic Conditions and Improve Patient Care and Outcomes

NEW YORK -- In third graph of release dated Oct. 27, 2008, the second sentence should be removed. Third graph should read:

The impact of RA on the national economy continues to grow. Cost drivers include delayed diagnosis and treatment of RA with TNF antagonists, which have been shown to reduce disease activity and slow or stop joint destruction. Additionally, patients diagnosed with early RA often are not treated within an appropriate time, resulting in early structural joint damage and loss of function. Compounding the problem is that physicians face a wide array of options, complicating the determination of the ideal therapeutic strategy for their patients.

The corrected release reads:

UNIVERSITY OF KENTUCKY LAUNCHES CLINICAL OUTCOMES-BASED EDUCATIONAL INITIATIVE TO REINFORCE RHEUMATOID ARTHRITIS (RA) STANDARDS OF CARE

Program to Address Physician Gaps in Managing Rheumatic Conditions and Improve Patient Care and Outcomes

The University of Kentucky Pharmacy and Medicine Continuing Education Office (UKPMCE) announced today the launch of the Rheumatoid Arthritis Educational Challenge (RAEC), which will address deficits in the treatment of rheumatic diseases, particularly rheumatoid arthritis (RA). The multi-interventional, integrated series of educational activities are designed to help rheumatologists and related physicians that treat RA apply the latest evidence-based standards of care to maximize outcomes for patients with RA.

"The RAEC takes a unique perspective on influencing appropriate practice behavior of physicians to overcome barriers that prevent them from managing RA effectively," said Philip J. Mease, M.D., Chief of Rheumatology Research at Swedish Medical Center and Clinical Professor of Medicine at the University of Washington in Seattle. "The initiative will assess specific provider and patient measures that must be addressed for improvements in outcomes to occur. The goal is to combine early diagnosis and treatment practices with accurate assessment of disease status and treatment response through various clinical measures, imaging techniques and biomarkers to advance clinical outcomes and chance of remission."

The impact of RA on the national economy continues to grow. Cost drivers include delayed diagnosis and treatment of RA with TNF antagonists, which have been shown to reduce disease activity and slow or stop joint destruction. Additionally, patients diagnosed with early RA often are not treated within an appropriate time, resulting in early structural joint damage and loss of function. Compounding the problem is that physicians face a wide array of options, complicating the determination of the ideal therapeutic strategy for their patients.

To enable physicians to meet these challenges, UKPMCE is overseeing the RAEC program to help them:

* Understand the benefits of an aggressive treatment-to-target strategy in the early management of RA

* Apply appropriate, integrated referral and care pathways for multidiscipline management of patients with RA and comorbid conditions, including atypical cases

* Utilize the risk / benefit profiles and appropriate administration of biological / TNF antagonist therapies in the management of RA patients

* Learn appropriate patient-physician communication skills for discussing the rationale, benefits and risks of biological / TNF antagonist therapies in RA

Added Mease, "The challenge is to enable rheumatologists to move beyond knowing and understanding standards of care and treatment guidelines into implementing and practicing those standards. The educational interventions of this initiative are designed to do just that--to assist practitioners in self-assessing and to empower them to close their own assessed practice gaps. In addition, the program will strengthen rheumatologists' patient-physician communication, disease and treatment assessment, as well as clinical decision-making skills in a manner that enhances patient care and outcomes."

Participants in the RAEC activity may qualify for CME credits through the University of Kentucky College of Medicine. The program is supported by an educational grant from Amgen, Inc. and Wyeth Pharmaceuticals. For more information or to register, visit http://www.cecentral.com/raec or call (908) 253-9001.

ABOUT THE UNIVERSITY OF KENTUCKY PHARMACY AND MEDICINE CONTINUING EDUCATION OFFICE

In accordance with the University of Kentucky's education, research and service missions, the Pharmacy and Medicine Continuing Education program delivers quality educational activities responsive to advances in medicine, pharmacotherapy and patient care with an emphasis on improving patient and population health in the Commonwealth of Kentucky. The program offers pharmacists, physicians and other healthcare professionals worldwide an opportunity to maintain and enhance their professional competencies in medicine and medication use through interactive, live activities and enduring materials. For more information, please visit http://www.ukyce.com/.>